Sumitomo Dainippon Pharma and its U.S. subsidiary SMPA announced an updated agreement on March 15th with Otsuka Pharmaceutical for the joint development of four psychiatric and neurological compounds, including ulotaront and others, amending their original September 30, 2021, partnership.

FDA Clears Italfarmaco's Duvyzat™ (givinostat) for Treatment of Duchenne Muscular Dystrophy.

Indomethacin is a small NSAID that blocks the COX enzyme to reduce inflammation and pain.

Vertex has received authorization from the FDA to proceed with clinical trials for VX-407, a new drug candidate targeting the management of ADPKD.

On March 14, AstraZeneca plans to buy Amolyt Pharma, a biotech firm specializing in rare endocrine disorders, enhancing its Alexion unit with the phase III drug, eneboparatide, for hypoparathyroidism treatment.

Sosei Heptares reclaims complete control over HTL0027477 from GSK, a pioneering oral GPR35 activator set for clinical trials in treating inflammatory bowel conditions.

Loperamide, an FDA-approved small molecule drug since December 1976, is a puzzling substance that binds to opioid receptors.

ACELYRIN, INC. has revealed encouraging initial data from its Phase 1/2 studies for Lonigutamab. This first-of-its-kind, injectable treatment targeting IGF-1R has shown promising therapeutic effects in patients suffering from Thyroid Eye Disease.

On March 20th, Idorsia, a Swiss pharma, announced FDA approval for their drug TRYVIO™ (aprocitentan) to be used alongside other antihypertensives for treating uncontrolled hypertension in adults.

Entera Bio Unveils Strong Drug Absorption Results for Innovative Oral GLP-2 Hormone Pill Designed for Individuals with Short Gut Condition.

Approved by the FDA in March 1996, Fexofenadine is a puzzling small molecule drug that works as an H1 receptor antagonist.

23andMe Commences Early-Stage Clinical Evaluation of Its Bifunctional Antibody, 23ME-01473, Aimed at ULBP6.